-4bp/HbE C11
MURAi002-A
General
Cell Line |
|
| hPSCreg name | MURAi002-A |
| Cite as: | MURAi002-A |
| Alternative name(s) |
-4bp/HbE C11
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines | No similar lines found. |
| Last update | 21st August 2024 |
| Notes | iPSC derived from patient with Beta-thalassemia major (codon 41/42; -CTTT) / Hemoglobin E (codon 26; G>A) Disease |
| User feedback | |
Provider |
|
| Generator | Faculty of Medicine Ramathibodi Hospital (MURA) |
| Owner | Faculty of Medicine Ramathibodi Hospital (MURA) |
| Distributors | |
| Derivation country | Thailand |
External Databases |
|
| BioSamples | SAMEA115111637 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Additional restrictions:
The cell line can be obtained by third parties for research use only using an appropriate MTA. |
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 20-24 |
| Ethnicity | Thai |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA115111638 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Alternatives to consent are available? | No |
| Is there other documentation provided to the donor for consenting purposes? | No |
| Confirm that consent was obtained by a qualified professional | Yes |
| Has the donor agreed to be re-contacted? | Yes |
| Has the donor been informed about how her/his data will be protected? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| Does consent pertain to a specific research project? | Yes |
| Details on restriction to research project | Project name(Translated): Generation of integration-free iPSC from hematopoietic stem/progenitor cell of alpha- and beta-thalassemia patients for disease modeling (Available for further use in other related or non-related project without additional consent) |
| Does consent permit unforeseen future research, without further consent? | Yes |
| Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? | No |
| Does consent expressly prevent development of commercial products? | No |
| Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? | No |
| Does consent expressly permit storage of donated embryo/tissue for an unlimited time? | No |
| Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? | No |
| Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | No |
| a non-profit company? | No |
| a for-profit corporation? | No |
| Does consent expressly permit collection of genetic information? | Yes |
| Does consent expressly permit storage of genetic information? | Yes |
| Does consent prevent dissemination of genetic information? | No |
| Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? | No |
| Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? | No |
| Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | Yes |
| Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
| Does consent permit access to medical records of the donor? | No |
| Does consent permit access to any other source of information about the clinical treatment or health of the donor? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University |
| Approval number | COA.MURA2020/514 (sub); COA NO. MURA2018/268 (main) |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
| Name of accrediting authority involved? | Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University |
| Approval number | COA.MURA2020/514 (sub); COA NO. MURA2018/268 (main) |
| Do you have obligations to third parties in regard to the use of the cell line? | No |
| Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Addgene |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
hIPSC Derivation
General |
|
| Source cell type |
A blood cell progenitor or mother cell representing a slightly later stage than the blast cell; it has the capacity for both replication and differentiation, and has pluripotentiality, giving rise to precursors of various different blood cell lines, such as the proerythrocyte and myeloblast, which cannot self-replicate and must differentiate into more mature daughter cells.
Synonyms
|
| Source cell origin |
A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.
Synonyms
|
| Age of donor (at collection) | 20-24 |
| Collected in | 2019 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | Detection of the EBNA region shared in all used reprogramming episomes (refer to vector map) (Amplicon size = 155bp) |
| Files and images showing reprogramming vector expressed or silenced | |
| Vector map | |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
Small molecules
|
| Small molecules |
|
Other |
|
| Selection criteria for clones | Criteria for clone selection by manual isolation during the initial D14-D21 reprogramming stage includes: iPSC-like colonies which are compact, has well-defined borders, shows high nucleus to cytoplasm ratio, and shows minimal signs of spontaneous differentiation or transformation (ex. Spiked borders). Later clone selection (at P9 and beyond) and iPSC line establishment criteria includes the absence of exogenous reprogramming plasmids in the cells, the presence of iPSC-related markers at the mRNA and protein level, and the capability to differentiate into all 3 germ layers. |
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzyme-free cell dissociation
EDTA
|
||||||
| O2 Concentration | 20 % | ||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ Plus
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| Actin Alpha 2, Smooth Muscle Actin (SMA) |
Yes |
| BRACHYURY/TBXT |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.